IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy - Full Text View

IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

This study has been terminated.

Sponsors and Collaborators:	University of Zurich ImVision AG
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00620880

Purpose

Primary objective of the trial:

To determine at which concentration the fusion protein MAT Fel d1 degranulates basophils of cat dander allergic patients, in comparison to a cat dander extract and to Fel d1 alone

Condition	Intervention
Allergy to Cats	Behavioral: Blood sample

MedlinePlus related topics:

Allergy

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Further study details as provided by University of Zurich:

Study Start Date:	September 2005
Estimated Study Completion Date:	November 2006

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria: 1. Patient with Cat Dander Allergy evidenced by positive history 2. Age: 18 to 75 years

Exclusion criteria: 1. Use of oral corticosteroids, Chromoglycin, Ketotifen, or any immunosuppressive drugs within the last 2 months 2. Psychiatric disorder resulting in malcompliance 3. Neg. IgE to Cat dander

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00620880

Locations


Switzerland

	Zurich, Switzerland

Sponsors and Collaborators

University of Zurich

ImVision AG

Investigators


Study Director:	01 Studienregister MasterAdmins	UniversitaetsSpital Zuerich

More Information

Study ID Numbers:	IVN-CAT-001A
First Received:	February 11, 2008
Last Updated:	February 11, 2008
ClinicalTrials.gov Identifier:	NCT00620880
Health Authority:	Switzerland: UZurich

Study placed in the following topic categories:

Hypersensitivity

Hypersensitivity, Immediate

ClinicalTrials.gov processed this record on August 20, 2008